HC Wainwright & Co. Assumes Spruce Biosciences at Buy, Announces Price Target of $220

Benzinga · 12/22/2025 11:31
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $220.